Abstract
A series 3/4-bromo-N'-(substituted benzylidene/furan-2-ylmethylene/5-oxopentylidene/3- phenylallylidene)benzohydrazides (1-23) was synthesized and characterized by physicochemical and spectral means. The synthesized compounds were screened for their antimicrobial and anticancer potentials. Antimicrobial activity results indicated that compound 12 (pMICam = 1.67 μM/ml) was the most potent antimicrobial agent. The synthesized benzohydrazides were also having good anticancer potential and compound 22 (IC50 = 1.20 μM μM) was found to be the most potent anticancer agent which was more potent than standard drugs, tetrandrine (IC50 = 1.53) and 5- fluorouracil (IC50 = 4.6 μM). QSAR studies indicated that antimicrobial activity of synthesized compounds was best described by electronic parameter, total energy (Te) and topological parameters, valance zero order molecular connectivity index (0χv) and Wiener index (W).
Keywords: Anticancer activity, Antimicrobial activity, Benzohydrazides, Minimum bactericidal/fungicidal concentration, Minimum inhibitory concentration, QSAR studies.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Synthesis, Antimicrobial, Anticancer Evaluation and QSAR Studies of 3/4-Bromo Benzohydrazide Derivatives
Volume: 15 Issue: 11
Author(s): Pradeep Kumar, Balasubramanian Narasimhan, Kalavathy Ramasamy, Vasudevan Mani, Rakesh Kumar Mishra and Abu Bakar Abdul Majeed
Affiliation:
Keywords: Anticancer activity, Antimicrobial activity, Benzohydrazides, Minimum bactericidal/fungicidal concentration, Minimum inhibitory concentration, QSAR studies.
Abstract: A series 3/4-bromo-N'-(substituted benzylidene/furan-2-ylmethylene/5-oxopentylidene/3- phenylallylidene)benzohydrazides (1-23) was synthesized and characterized by physicochemical and spectral means. The synthesized compounds were screened for their antimicrobial and anticancer potentials. Antimicrobial activity results indicated that compound 12 (pMICam = 1.67 μM/ml) was the most potent antimicrobial agent. The synthesized benzohydrazides were also having good anticancer potential and compound 22 (IC50 = 1.20 μM μM) was found to be the most potent anticancer agent which was more potent than standard drugs, tetrandrine (IC50 = 1.53) and 5- fluorouracil (IC50 = 4.6 μM). QSAR studies indicated that antimicrobial activity of synthesized compounds was best described by electronic parameter, total energy (Te) and topological parameters, valance zero order molecular connectivity index (0χv) and Wiener index (W).
Export Options
About this article
Cite this article as:
Kumar Pradeep, Narasimhan Balasubramanian, Ramasamy Kalavathy, Mani Vasudevan, Kumar Mishra Rakesh and Abdul Majeed Abu Bakar, Synthesis, Antimicrobial, Anticancer Evaluation and QSAR Studies of 3/4-Bromo Benzohydrazide Derivatives, Current Topics in Medicinal Chemistry 2015; 15 (11) . https://dx.doi.org/10.2174/156802661511150408111252
DOI https://dx.doi.org/10.2174/156802661511150408111252 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Fabrication and Evaluation of Colon Targeted Uricase Containing Microbeads for Treatment of Gout
Drug Delivery Letters Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer
Current Cancer Drug Targets Alternative Polyadenylation and Its Impact on Cellular Processes
MicroRNA Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets Glycomics: Relevance for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Prediction of Chemical Multi-target Profiles and Adverse Outcomes with Systems Toxicology
Current Medicinal Chemistry Formulation, Characterization and <i>In-vitro</i> and <i>In-vivo</i> Evaluation of Capecitabine Loaded Niosomes
Current Drug Delivery Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network
Letters in Drug Design & Discovery